Boston Trust Walden Corp grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 13.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 915,722 shares of the medical instruments supplier's stock after purchasing an additional 106,114 shares during the quarter. Boston Trust Walden Corp owned approximately 1.82% of Haemonetics worth $71,500,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in HAE. Wellington Management Group LLP grew its stake in shares of Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock valued at $337,722,000 after purchasing an additional 363,702 shares during the last quarter. Royce & Associates LP boosted its holdings in Haemonetics by 2.6% in the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier's stock valued at $97,304,000 after acquiring an additional 30,868 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock worth $95,986,000 after acquiring an additional 21,547 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier's stock valued at $88,433,000 after purchasing an additional 250,833 shares during the period. Finally, Westfield Capital Management Co. LP boosted its stake in Haemonetics by 10.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock valued at $66,206,000 after acquiring an additional 80,783 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Price Performance
Shares of HAE traded down $8.29 during midday trading on Thursday, reaching $62.95. The stock had a trading volume of 3,476,898 shares, compared to its average volume of 873,365. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 1.07 and a beta of 0.39. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a 12-month low of $61.43 and a 12-month high of $97.97. The company's 50-day moving average is $77.44 and its 200 day moving average is $78.73.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. On average, equities analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.
Analyst Ratings Changes
HAE has been the topic of several analyst reports. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an "overweight" rating and a $116.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $112.00 price objective on shares of Haemonetics in a research report on Tuesday, December 3rd. Raymond James raised Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective for the company in a research report on Friday, November 8th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a report on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average target price of $108.78.
Check Out Our Latest Research Report on HAE
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Recommended Stories
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
